In November 2020, Oregon made history by becoming the first U.S. state to legalize psilocybin, the active ingredient in so-called magic mushrooms. Much like cannabis, psychedelics are becoming more mainstream, and investors are sizing up what could be a major long-term growth opportunity. Market research firm Research and Markets recently estimated that the psychedelic drugs market will reach $10.75 billion by 2027. Unfortunately, cannabis stock investors know the nascent business has faced many regulatory hurdles and experienced multiple boom and bust cycles, so psychedelics investors must have a high risk tolerance. Here are seven top psychedelics stocks to watch. Mind Medicine Inc. (MNMD) ATAI Life Sciences (ATAI) GH Research PLC (GHRS) Compass Pathways PLC (CMPS) Cybin Inc. (CYBN) Seelos Therapeutics Inc. (SEEL) Field Trip Health Ltd. (FTRP)
Firm believer here. As an experienced psychonaught , I know these markets will do well and that the government is wrongfully holding back these therapeutic chemicals that can help millions of people.